Old name, new purpose: why we’ve gone back to RNID

Fellowship scheme

Our Fellowship scheme aims to build research capacity in hearing research, by supporting the career development of the UK’s most talented new ‘investigators’ towards becoming independent scientists.

For this year’s scheme, we are working with the Dunhill Medical Trust to fund these fellowships.

The fellowship supports salary and project costs for 2 years, up to a total of £120,000.

Applications are invited in any of the following areas:

  • Research to underpin the development of treatments for hearing disorders, including tinnitus. Including, but not limited to, medical devices, pharmacological treatments, genetic or cellular therapies – treatments should aim to prevent hearing loss, restore auditory function or silence tinnitus.
  • Research to improve how new treatments for hearing disorders, including tinnitus, are developed and tested. Including research to improve the measurement of auditory function or tinnitus, or to develop models of human hearing disorders, including tinnitus.

Applications with a focus on understanding the mechanisms of age-related hearing conditions, or how ageing affects the auditory system, are especially encouraged, and will be considered for joint funding.

Projects should bring tangible benefits closer for people who are deaf, have tinnitus or hearing loss.

Summary of the fellowship

  • Value: Up to £120,000  
  • Duration: Usually 24 months
  • Eligibility: You must be an early career investigator who has the desire and potential to become an independent scientist in the field of hearing research. You must hold a PhD and you can be based at any UK university or research institute, but you must not be a permanent employee. The award should support your progression towards an independent research career. 
  • Deadline: Closed. The next call for applications will be launched in late 2022.

In the last round of funding (2021), we received 6 applications and awarded 2 fellowships.

How to apply

To apply, download the guidelines, application form and application form guidance:

Selection procedure

Eligible proposals will be reviewed by two or three external reviewers. These reviews and the original proposals will then be considered by our Future Leaders Review Panel who will rank the proposals and shortlist candidates for interview.

Interviews will take place in May – the final date will be confirmed with you when you submit your application. Short-listed candidates will be informed no less than 2 weeks before the interview date, and given further instructions for the interview then.

Interviews will be conducted by the Future Leaders Review Panel. Following the interviews, the panel will make funding recommendations to RNID and the Dunhill Medical Trust.

Everyone involved in the review process of any grant application is asked to abide by our code of conduct.

Applicants will be notified of the outcome as soon as possible following the final decision.

Future Leaders Review Panel

  • Professor Brian Moore, University of Cambridge (chair)
  • Dr Christian Füllgrabe, University College London
  • Dr Dan Jagger, University College London
  • Dr Morag Lewis, King’s College London
  • Professor Jennifer Linden, University College London
  • Professor Walter Marcotti, University of Sheffield
  • Professor Christopher Plack, University of Manchester
  • Dr William Sedley, Newcastle University
  • Professor Andrea Streit, King’s College London
  • Dr Deborah Vickers, University of Cambridge
  • Dr Mark Wallace, University of Nottingham
  • Additional members from the Dunhill Medical Trust Advisory Panel to be confirmed.

Europe PubMed Central (Europe PMC) and open access publications

RNID is a member of the Europe PMC Funders’ Group. We support open access publications and require RNID grant-holders to make their publications open access.

Read our open access publication policy for more information and visit the Europe PMC website.

Contact RNID

If you have any questions or need more information, you can contact us. We’re here to help.